Video Experimental Relacionado
Updated: Aug 18, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Resumen de los ensayos clínicos en curso de medicamentos con actividad plaquetaria en enfermedades cardiovasculares
Circulation
|December 1, 1980
Resumen
Diecisiete ensayos clínicos están evaluando fármacos activadores de las plaquetas para prevenir eventos cardíacos y cerebrales. Los diseños de ensayos varían en su capacidad para detectar los efectos del tratamiento, y la mayoría de los resultados se esperan pronto.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Farmacología clínica Farmacología clínica.
- Cardiología Preventiva Cardiología preventiva.
Sus antecedentes:
- Los fármacos con actividad plaquetaria son cruciales para prevenir los eventos atero-trombóticos.
- Numerosos ensayos clínicos están investigando regímenes óptimos de medicamentos.
- Comprender el diseño del ensayo es clave para interpretar los resultados futuros.
Objetivo del estudio:
- Para resumir las características de diseño de los ensayos clínicos en curso.
- Evaluar el poder estadístico de estos ensayos para detectar efectos clínicamente significativos.
- Proporcionar una visión general del panorama de investigación actual en la prevención de drogas activas en las plaquetas.
Principales métodos:
- Revisión y síntesis de las características de diseño de 17 ensayos clínicos en curso.
- Análisis del poder estadístico y consideraciones sobre el tamaño de la muestra.
- Categoría de los ensayos basados en el tipo de prevención (primaria/secundaria) y el objetivo de la enfermedad (coronaria/cerebrovascular).
Principales resultados:
- Existe una heterogeneidad significativa en los diseños de los ensayos y en el poder estadístico.
- Algunos ensayos tienen un poder limitado para detectar efectos de tratamiento modestos pero potencialmente importantes.
- La mayoría de los ensayos están a punto de concluir, y se esperan resultados en los próximos años.
Conclusiones:
- El panorama actual de ensayos clínicos para fármacos antiplaquetarios activos es diverso.
- La interpretación de los resultados de ensayos futuros requerirá una cuidadosa consideración de las metodologías de ensayos individuales y de la potencia.
- La investigación en curso está preparada para proporcionar información valiosa sobre el papel de estos agentes en la prevención de enfermedades cardiovasculares y cerebrovasculares.
Videos de Conceptos Relacionados
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...